Using in silico analysis of clinically derived platforms, we report a decreased BDP1 expression as a result of deletion in serous ovarian cancer and a correlation with higher and advanced ovarian stages. Further analysis in the context of TP53 mutations, a major contributor to ovarian tumorigenesis, suggests that high BDP1 expression is unfavorable for overall survival and high BDP1 expression occurs in stages 2, 3 and 4 serous ovarian cancer. Additionally, high BDP1 expression is disadvantageous and unfavorable for progression-free survival. Lastly, BDP1 expression significantly decreased in patients treated with first-line chemotherapy, platin and taxane, at twelve-month relapse-free survival.
Taken together with a ROC analysis, the data suggest BDP1 could be of clinical relevance as a predictive biomarker in serous ovarian cancer. Lastly, this study further demonstrates that both the over- and under expression of BDP1 warrants further investigation and suggests BDP1 may exhibit dual function in the context of tumorigenesis.
结果:使用临床衍生平台的计算机模拟分析,我们报道了由于浆液性卵巢癌中的缺失而导致的BDP1表达下降,并且与卵巢高发和晚期阶段相关。在TP53突变的背景下进行进一步分析,卵巢肿瘤发生的主要原因,提示高BDP1表达不利于总生存期,高BDP1表达发生在2、3和4期浆液性卵巢癌中。此外,高BDP1表达对无进展生存期不利。最后,在接受一线化疗的患者中,BDP1表达显著下降,铂和紫杉烷,在12个月无复发生存期。
结论:结合ROC分析,数据提示BDP1作为浆液性卵巢癌的预测生物标志物可能具有临床意义.最后,这项研究进一步证明了BDP1的过表达和过表达不足都值得进一步研究,并提示BDP1在肿瘤发生背景下可能表现出双重功能。